AtriCure (ATRC) Canaccord Genuity's 46th Annual Growth Conference summary

Strategic focus and market leadership

• Focused on treating complex AFib and post-surgical pain using ablation and left atrial appendage management, holding the top position in all served markets.

• Achieved consistent 18% CAGR over five years, with recent quarters showing profitability, 77% gross margins, and positive cash flow.

• Addressing a total addressable market (TAM) exceeding $10 billion, with 2023 revenue guidance of $602–$610 million and presence in 58 countries.

• Long-range plan targets $1 billion revenue by 2030 and 20% adjusted EBITDA, already outperforming interim milestones.

Clinical trials and innovation pipeline

• Major ongoing trials (LeAAPS and BoxX-NoAF) aim to expand indications and market size, with pivotal data expected mid-next year and by decade's end.

• LeAAPS trial (6,573 patients) is fully enrolled, targeting stroke reduction; BoxX-NoAF (1,000 patients) is ahead of schedule, targeting post-op AFib reduction.

• Both trials use proprietary technology exclusively, with anticipated label expansions and significant market penetration upside.

• Pain management franchise, launched in 2019, has grown rapidly to nearly $100 million, driven by cryotechnology for nerve block.

Financial performance and operational leverage

• Recent quarters saw beat-and-raise performance, strong EBITDA, and robust cash generation.

• Pain management growth is led by cryoSPHERE MAX, with 25% volume growth and 12% account growth, indicating deeper procedural adoption.

• Gross margin strength (77%) is driven by favorable product and geographic mix; new manufacturing facility may slightly reduce margins short-term.

• Operating leverage achieved across OpEx; R&D spend to increase in H2 due to trial activity, but EBITDA guidance remains strong.